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Cellular antigens of the TL (thymus-leukemia) system' 2 are identified by the following characteristics:
(1) They occur in certain strains of mice (TL+ strains) and are absent in others (TLstrains).
(2) In TL+ mice these antigens occur only in cells of the thymus; they are determined by a single locus, Tla, adjacent to the "D" end of the compound H-2 locus in linkage group IX (1.5% recombination) ; the thymus cells of heterozygotes contain half the quantity of antigen found in homozygotes.
(3) TLmice can form TL antibody but TL+ mice cannot, presumably because they are immunologically tolerant of the antigen.
(4) TL antigen is frequently present in leukemia cells from mice of TLstrains, i.e., from mice that do not possess the antigen in normal thymus; this has necessitated the hypothesis that mice of all strains, whether TL+ or TL -, have the structural gene for TL synthesis, but that in normal TLmice this is not expressed.
(5) TL antigen disappears from TL+ leukemias when these are passed in isogenic (TL -) mice immunized against TL; the antigen reappears on further passage of the leukemia in unimmunized hosts; this phenomenon of disappearance and reappearance of TL antigen has been termed antigenic modulation and is the subject of this report.
The three main questions with which we are concerned here are: Can antigenic modulation be brought about by immune serum? Can TL+ leukemias of mice of TL+ strains (that cannot be immunized against TL) undergo antigenic modulation? Can normal TL+ thymus cells undergo antigenic modulation?
The first of the experiments reported here was performed with ERLD, a TL+ leukemia of the C57BL/6 strain; C57BL/6 mice are TL-and so can be actively immunized against TL antigen. Leukemia ERLD is known to become TLon passage in C57BL/6 mice that have been immunized with an A strain TL+ leukemia. Figure 1 shows that suppression of TL antigen takes place when ERLD is passed in C57BL/6 mice receiving TL antibody.3 The fact that TL+ mice cannot be immunized against TL antigen precludes the use of actively immunized histocompatible hosts for the study of antigenic modulation of TL+ leukemias arising in TL+ strains. However, this can be investigated by transfer of immune serum. An example of complete suppression by TL anti-serum4 is shown in Figure 2 . Antigenic modulation is not confined to leukemia cells normal thymus cells of TL+ mice also undergo TL+ -TLconversion after exposure to TL antibody received by injection ( Fig. 3 ) or by maternal transfer (Fig. 4 ). In mice whose thymus cells have been modulated by maternal antibody, TL antigen returns after weaning ( Fig. 4 ). Dilution of TL antiserum
The implications of these results are as follows: TL antigen of both normal thymus cells and leukemias of TL+ strains is not more stable (i.e., is no more resistant to modulation by antibody) than the aberrant TL.1 antigen ofle ukemias in TLstrains.
The Tla locus of TL+ strains determines three antigens, TL.1, TL.2, and TL.3, of which TL.1 appears anomalously in leukemias of TL-strains.2 Figures 24 show that all three components can be suppressed by TL antibody-thus, susceptibility to antigenic modulation is a property of TL antigens as a class and is not confined to the component showing anomalous appearance in leukemias of TL-strains.
In the experiments illustrated in Figures 2 and 4 , antigenic modulation was produced by serum containing anti-TL. (2) Modulation occurs in vitro when TL+ cells are incubated with TL antibody, but the rate at which it occurs appears to be related to metabolic activity; modulation in vitro takes place rapidly (1 hr or less) with leukemias that have a short generation time but less rapidly with slow-growing leukemias and with TL+ thymus cells. Such differences would not be expected if modulation were caused by a blocking antibody; they suggest an active metabolic process. This view is further supported by our observation that treatment of TL+ leukemia cells with actinomycin D in vitro abolishes their capacity to modulate; furthermore, modulation does not occur when incubation is carried out at 40C rather than 37CC.
(3) The most impressive evidence against blocking antibody, however, is the demonstration that absence of TL antigen, both in phenotypically TLthymus cells and in leukemia cells that have undergone TL+ TLmodulation, is associated with a compensatory increase in the surface concentration of a different isoantigen. The evidence is as follows:
The close genetic linkage between H-2 and Tla suggested to us the possibility of a functional relation between these two loci, and so we investigated the content of H-2 antigen in various TL+ and TLcells of the same H-2 type. The C57BL/6 and the C57BL/6(TL+) strains are an excellent pair for comparison. (The C57BL/6 (TL+) stock originated from a backcross of strain A (TL+ :H-2) to C57BL/6 (TL -: H-2b).2 A female of the recombinant type TL+ :-2bwas serially backerossed to C57BL/6; TL+ homozygotes were obtained by crossing heterozygous progeny of the eighth backcross, and were inbred to provide the congenic C57BL/6(TL+) stock.) Table 1 shows that the thymus cells of C57BL/6(TL+) mice contain approximately half the quantity of H-2b antigen present in C57BL/6 mice. Lymphocytes from 80.0 * Diluted serum (0.06 ml. vol) was absorbed with counted numbers of each cell-type (optimal dilution of antiserum and range of cell numbers determined in preliminary tests) and tested for residual cytotoxic antibody; results for each cell-type were plotted as % viability in relation to numbers of cells used for absorption; the intercept of this curve with the level of 50% viability gives the figure in this column.
t The volumes of C57BL/6 and C57BL/6(TL+) thymus cells (measured by Coulter counter) are the same.
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GENETICS: BOYSE, STOCKERT, AND OLD both strains (obtained from lymph nodes) are phenotypically TL -, and they have equal quantities of H-2b antigen. The difference in content of H-2 antigen related to TL phenotype does not extend to another thymic isoantigen, O-C3H,5 which is not linked to the H-2: Tla complex (unpublished observation). Table 1 also shows that thymus cells of the 129 strain (H-2b: TL.2) contain half the quantity of H-2 antigen present in C57BL/6 (H-2b:TL -) thymus cells; once again, lymphocytes from the two strains have equal quantities of H-2 antigen. Later experiments indicate that these differences in content of H-2 antigen are confined to components specified by the "D" end of H-2, which is contiguous to Tla; H-2 components specified by the opposite ("K") end of H-2, which is distal to Tla, are not affected by TL phenotype. Similar quantitative absorptions of H-2 antisera have been carried out with the two TL+ leukemias ERLD and ASL1 after they had undergone modulation in actively or passively immunized hosts. These have shown comparable increases in H-2 antigen accompanying the loss of TL.
It is not yet decided whether the apparently lower content of H-2 antigen ill TL+ cells denotes less synthesis, or whether H-2 antigen is sterically masked by TL antigen and so rendered less efficient in absorbing H-2 (D region) antibody. The latter explanation would entail that the pattern of H-2: TL antigens on the cell membrane reflects the sequence of H-2: Tla genes. The recent separation of H-2 and TL antigens by solubilization and chromatography6 indicates that this would involve the ordered apposition of at least two molecules rather than the positioning of determinants on a single molecule.
Surmmary.-The phenotypic expression of TL antigens ill normal thymus cells and in leukemia cells can be suppressed (antigenic modulation) by TL antibody. The thymus cells of genotypically TL+ mice suckled on mothers highly immunized against TL become phenotypically TLas a consequence of maternal transfer of TL antibody. The content of H-2 isoantigen in thymus cells of TLmice is greater than that of TL+ (TL.2 or TL.1,2,3) mice carrying the same H-2 alleles. Modulation of components TL.1,3 by antiserum against TL.1,3 entails modulation of TL.2 in the absence of anti-TL.2. Antigenic modulation appears to depend upon an active metabolic process by the affected cells.
